AUD 0.02
(0.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 | -2.54 Million NZD | 13.4% |
2023 | -2.94 Million NZD | 64.44% |
2022 | -8.27 Million NZD | -194.56% |
2021 | -2.8 Million NZD | -30.83% |
2020 | -2.14 Million NZD | 26.2% |
2019 | -2.78 Million NZD | 37.64% |
2018 | -4.66 Million NZD | -56.81% |
2017 | -2.97 Million NZD | -243.71% |
2016 | -871.88 Thousand NZD | -41.84% |
2015 | -610.22 Thousand NZD | 73.85% |
2014 | -2.33 Million NZD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | -43.51 Thousand NZD | 100.0% |
2024 Q3 | -56.12 Thousand NZD | 0.0% |
2024 FY | - NZD | 13.4% |
2024 Q2 | -43.51 Thousand NZD | 0.0% |
2024 Q4 | -56.12 Thousand NZD | 0.0% |
2023 Q2 | -619.88 Thousand NZD | 0.0% |
2023 Q3 | -537.85 Thousand NZD | 13.23% |
2023 Q1 | -619.88 Thousand NZD | 31.04% |
2023 FY | - NZD | 64.44% |
2023 Q4 | -430.68 Thousand NZD | 19.93% |
2022 Q4 | -898.97 Thousand NZD | 0.0% |
2022 FY | - NZD | -194.56% |
2022 Q3 | -898.97 Thousand NZD | -75.43% |
2022 Q2 | -512.43 Thousand NZD | 0.0% |
2022 Q1 | -512.43 Thousand NZD | 28.69% |
2021 Q1 | -550.64 Thousand NZD | 29.86% |
2021 FY | - NZD | -30.83% |
2021 Q2 | -550.64 Thousand NZD | 0.0% |
2021 Q4 | -718.6 Thousand NZD | 0.0% |
2021 Q3 | -718.6 Thousand NZD | -30.5% |
2020 Q3 | -785.08 Thousand NZD | -128.76% |
2020 Q2 | -343.19 Thousand NZD | 0.0% |
2020 FY | - NZD | 26.2% |
2020 Q4 | -785.08 Thousand NZD | 0.0% |
2020 Q1 | -343.19 Thousand NZD | 52.56% |
2019 Q3 | -723.38 Thousand NZD | -33.01% |
2019 Q1 | -543.87 Thousand NZD | 44.24% |
2019 Q2 | -543.87 Thousand NZD | 0.0% |
2019 Q4 | -723.38 Thousand NZD | 0.0% |
2019 FY | - NZD | 37.64% |
2018 FY | - NZD | -56.81% |
2018 Q3 | -975.39 Thousand NZD | -38.42% |
2018 Q4 | -975.39 Thousand NZD | 0.0% |
2018 Q1 | -704.66 Thousand NZD | 27.08% |
2018 Q2 | -704.66 Thousand NZD | -0.0% |
2017 Q2 | -520.26 Thousand NZD | -0.0% |
2017 Q4 | -966.38 Thousand NZD | 0.0% |
2017 FY | - NZD | -243.71% |
2017 Q3 | -966.38 Thousand NZD | -85.75% |
2017 Q1 | -520.26 Thousand NZD | -53.45% |
2016 Q1 | -150.04 Thousand NZD | -289.65% |
2016 FY | - NZD | -41.84% |
2016 Q3 | -339.03 Thousand NZD | -125.97% |
2016 Q4 | -339.03 Thousand NZD | 0.0% |
2016 Q2 | -150.04 Thousand NZD | 0.0% |
2015 Q2 | -256.38 Thousand NZD | 0.0% |
2015 Q3 | 79.11 Thousand NZD | 130.86% |
2015 FY | - NZD | 73.85% |
2015 Q4 | 79.11 Thousand NZD | 0.0% |
2015 Q1 | -256.39 Thousand NZD | 0.0% |
2014 FY | - NZD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
4DMedical Limited | -36.06 Million AUD | 92.936% |
Adherium Limited | -11.56 Million AUD | 77.971% |
Aroa Biosurgery Limited | -7.36 Million AUD | 65.387% |
Atomo Diagnostics Limited | -5.42 Million AUD | 53.027% |
Anteris Technologies Ltd | -66.9 Million AUD | 96.192% |
Control Bionics Limited | -5.15 Million AUD | 50.611% |
CardieX Limited | -6.71 Million AUD | 62.044% |
Compumedics Limited | 2.78 Million AUD | 191.344% |
Cochlear Limited | 579.5 Million AUD | 100.44% |
CleanSpace Holdings Limited | -3.49 Million AUD | 27.041% |
Cyclopharm Limited | -3.03 Million AUD | 16.057% |
EMVision Medical Devices Ltd | -2.09 Million AUD | -21.823% |
Nova Eye Medical Limited | -5.97 Million AUD | 57.391% |
HeraMED Limited | -3.97 Million AUD | 35.863% |
Imricor Medical Systems, Inc. | -21.87 Million AUD | 88.351% |
ImpediMed Limited | -22.05 Million AUD | 88.447% |
InhaleRx Limited | -1.41 Million AUD | -80.201% |
LBT Innovations Limited | -4.04 Million AUD | 37.081% |
Micro-X Limited | -14.35 Million AUD | 82.248% |
Neurotech International Limited | -8.24 Million AUD | 69.098% |
OncoSil Medical Limited | -11.97 Million AUD | 78.728% |
PolyNovo Limited | 5.17 Million AUD | 149.276% |
Respiri Limited | -7.04 Million AUD | 63.864% |
SomnoMed Limited | -2.32 Million AUD | -9.403% |
Universal Biosensors, Inc. | -9.09 Million AUD | 71.975% |
Uscom Limited | -1.5 Million AUD | -68.791% |
Visioneering Technologies, Inc. | -4.91 Million AUD | 48.193% |